Cost effectiveness of screening for bowel cancer | Deloitte Australia | Deloitte Access Economics has been added to your bookmarks.
Cost-effectiveness of screening for bowel cancer
Deloitte Access Economics report
Commissioned by The Gut Foundation this report analyses the cost-effectiveness of bowel cancer screening relative to the comparator of ‘no screening’.
Australia has one of the highest rates of bowel cancer in the world. It is the second most commonly diagnosed cancer nationally and the second single leading cause of cancer death (AIHW, 2010). There were an estimated 14,234 new cases of bowel cancer in 2007 and 4,047 deaths that year from the disease.
This report provides a cost effectiveness analysis (CEA) of bowel cancer screening relative to the comparator of ‘no screening’. From the CEA we draw conclusions regarding different screening interventions and the benefits they have for the Australian population.